Jul 23, 2026 08:01AM
Jul 23, 2026 08:01AM
Jul 8, 2026 07:30AM
Jul 8, 2026 07:30AM
Jun 2, 2026 08:15AM
Jun 2, 2026 08:13AM
May 19, 2026 07:30AM Lantern Pharma receives FDA clearance for HARMONIC trial amendments
May 19, 2026 07:30AM
May 15, 2026 04:01PM
May 14, 2026 04:05PM
May 14, 2026 04:05PM
May 14, 2026 04:05PM
May 13, 2026 08:00AM
May 13, 2026 08:00AM Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
May 11, 2026 04:30PM
May 7, 2026 09:01AM
May 7, 2026 09:01AM
Apr 29, 2026 08:50AM
Apr 24, 2026 07:50AM
Apr 20, 2026 08:05AM
Apr 20, 2026 08:05AM Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With
Apr 14, 2026 08:36AM
Apr 14, 2026 08:31AM
Apr 2, 2026 08:10AM
Mar 30, 2026 04:05PM
Mar 27, 2026 07:29AM
Mar 27, 2026 07:29AM
Mar 23, 2026 04:30PM Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Feb 10, 2026 08:45AM
Jan 20, 2026 08:04AM
Jan 20, 2026 08:00AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Dec 3, 2025 08:35AM
Dec 3, 2025 08:35AM Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into M
Nov 13, 2025 08:30AM
Nov 6, 2025 08:00AM
Oct 30, 2025 08:00AM
Oct 28, 2025 08:50AM
Oct 28, 2025 08:49AM
Oct 24, 2025 08:00AM
Sep 16, 2025 08:29AM Lantern Pharma completes LP-184 phase 1a trial meeting primary endpoints
Sep 16, 2025 08:29AM
Sep 3, 2025 09:44AM
Sep 3, 2025 09:44AM
Aug 19, 2025 08:00AM
Aug 13, 2025 04:30PM
Aug 6, 2025 08:30AM
Aug 6, 2025 08:30AM Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Aug 4, 2025 08:55AM

326,514 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All